{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:06:31Z","timestamp":1789016791737,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lymphoma patients often receive high glucocorticoid doses as part of standard therapy. Observational studies have shown a substantial risk of glucocorticoid-induced osteoporosis (GIO) with associated fractures. The aim of the SIESTA trial was to determine if oral alendronate (ALN) is a safe and effective prophylaxis against GIO in lymphoma. SIESTA was a single-center, randomized, double-blinded, phase 2 study of lymphoma patients planned for glucocorticoid-containing chemotherapy. After randomization, patients received weekly ALN 70 mg or placebo for a total of 52 weeks. Bone mineral density (BMD) was assessed at baseline, after completion of chemotherapy (end of treatment [EOT]) (4 to 6 months), and at the end of the study (EOS) (12 months). Vertebral fracture and biomarkers were assessed at baseline and EOS. Patients with baseline BMD assessment and at least 1 follow-up BMD assessment were analyzed for efficacy. The primary endpoint was a change in lumbar spine T-score from baseline to EOS. Of the 59 patients enrolled, 23 of 30 in the ALN arm and 24 of 29 in the placebo arm were analyzed for efficacy. The mean change in T-score from baseline to 12 months at the lumbar spine was +0.15 for ALN and -0.12 for placebo (P = .023). The difference in \u0394TEOS between the ALN and placebo groups was larger among females (ALN 0.28; placebo -0.28; P = .01). Biomarker analyses confirmed reduced bone resorption in ALN-treated patients. In conclusion, ALN is a safe and effective primary prophylaxis against loss in BMD following glucocorticoid-containing chemotherapy. Despite reduced BMD loss in the ALN arm, the treatment did not influence fracture risk in this small cohort of patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006330","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:25:14Z","timestamp":1642616714000},"page":"2549-2556","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-0523","authenticated-orcid":false,"given":"Paw","family":"Jensen","sequence":"first","affiliation":[{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Hjort","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f8gsted","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;"},{"name":"Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-4879","authenticated-orcid":false,"given":"Joachim","family":"Baech","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lykkeboe","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-1812","authenticated-orcid":false,"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;"},{"name":"Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark;"},{"name":"Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark; and"},{"name":"Steno Diabetes Center North Denmark, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark;"},{"name":"Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, Aalborg, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"issue":"11","key":"2022041915224253000_B1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol."},{"issue":"4","key":"2022041915224253000_B2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med."},{"issue":"1","key":"2022041915224253000_B3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"LoCascio","year":"1990","journal-title":"Bone Miner."},{"issue":"4","key":"2022041915224253000_B4","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/jcp.27335","article-title":"Osteoblast autophagy in glucocorticoid-induced osteoporosis","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol."},{"issue":"2","key":"2022041915224253000_B5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest."},{"issue":"12","key":"2022041915224253000_B6","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology."},{"issue":"8","key":"2022041915224253000_B7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol."},{"issue":"9","key":"2022041915224253000_B8","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int."},{"issue":"1\u20132","key":"2022041915224253000_B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-012-0070-7","article-title":"An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis","volume":"7","author":"Lekamwasam","year":"2012","journal-title":"Arch Osteoporos."},{"issue":"5","key":"2022041915224253000_B10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/10428194.2016.1233543","article-title":"R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients","volume":"58","author":"Svendsen","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"8","key":"2022041915224253000_B11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428190701471973","article-title":"Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures","volume":"48","author":"Cabanillas","year":"2007","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2022041915224253000_B12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428194.2020.1723015","article-title":"Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study","volume":"61","author":"Baech","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022041915224253000_B13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2022041915224253000_B14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.beem.2018.05.003","article-title":"Bone turnover: biology and assessment tools","volume":"32","author":"Szulc","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"10","key":"2022041915224253000_B15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","article-title":"Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study","volume":"119","author":"Laan","year":"1993","journal-title":"Ann Intern Med."},{"issue":"8","key":"2022041915224253000_B16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.amjmed.2003.12.019","article-title":"Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy","volume":"116","author":"Kim","year":"2004","journal-title":"Am J Med."},{"issue":"2","key":"2022041915224253000_B17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clml.2012.11.002","article-title":"Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial","volume":"13","author":"Westin","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"8","key":"2022041915224253000_B18","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1359\/jbmr.2005.20.8.1486","article-title":"Use of oral corticosteroids and risk of fractures. June, 2000","volume":"20","author":"Van Staa","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2022041915224253000_B19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdt560","article-title":"Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study","volume":"25","author":"Paccou","year":"2014","journal-title":"Ann Oncol."},{"issue":"18","key":"2022041915224253000_B20","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/bloodadvances.2020002553","article-title":"Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma","volume":"4","author":"Booth","year":"2020","journal-title":"Blood Adv."},{"issue":"0","key":"2022041915224253000_B21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","article-title":"Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status","volume":"87","author":"Curtis","year":"2016","journal-title":"Bone."},{"issue":"7041","key":"2022041915224253000_B22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ."},{"issue":"8","key":"2022041915224253000_B23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"2022041915224253000_B24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/0284186X.2016.1267870","article-title":"Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation","volume":"56","author":"Seland","year":"2017","journal-title":"Acta Oncol."},{"issue":"21","key":"2022041915224253000_B25","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1158\/1078-0432.CCR-06-1382","article-title":"Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma","volume":"12","author":"Brown","year":"2006","journal-title":"Clin Cancer Res."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2549\/1891336\/advancesadv2021006330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2549\/1891336\/advancesadv2021006330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:52:15Z","timestamp":1700077935000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/8\/2549\/483569\/A-randomized-trial-of-alendronate-as-prophylaxis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006330","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}